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This study aims to deepen understanding of lymphocyte phenotypes related to the course of 
hepatitis C virus (HCV) infection and progression of liver fibrosis, in a cohort of 
atomic-bomb survivors.  The study subjects comprise three groups: 162 HCV persistently 
infected, 145 spontaneously cleared, and 3511 uninfected individuals.  We found increased 
percentages of peripheral blood TH1 and total CD8 T cells and decreased percentages of NK 
cells in the HCV persistence group, compared with the other two groups, after adjustment for 
age, gender, and radiation exposure dose.  Subsequently, we found that increased TH1 cell 
percentages in the HCV persistence group were significantly associated with an accelerated 
time-course reduction in platelet counts―accelerated progression of liver fibrosis―while TC1 
and NK cell percentages were inversely associated with the progression.  This study suggests 
that TH1 immunity is enhanced by persistent HCV infection, and that percentages of 
peripheral TH1, TC1, and NK cells may help predict progression of liver fibrosis. 
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1. Introduction 
HCV infects some 120-170 million people worldwide, and persistent HCV infection is a 
major cause of liver diseases including chronic hepatitis, cirrhosis, and hepatocellular 
carcinomas [1, 2].  It is now widely recognized that both innate and adaptive arms of the 
host immune system are closely involved in persistent infection, liver injury, and virus 
clearance [3, 4].  For instance, cytotoxic granule release and cytokine production of NK cells 
are inhibited by direct binding of HCV envelope protein E2 to CD81 on NK cells, or 
stabilizing the HLA-E expressions on hepatocytes in HCV-infected patients [5, 6].  However, 
comprehensive understanding of interactions between HCV and the immune system remains 
incomplete [3, 4].  Moreover, aging, gender, and several environmental factors such as 
alcohol drinking, smoking, and ionizing radiation have been reported to influence host 
immune functions as well as HCV spontaneous clearance [7-9], which may increase the 
complexity of virus-host interactions.  Therefore, a comprehensive characterization of host 
immunological phenotypes in HCV infection is needed, especially with a cohort-based study 
design without conceivable selection bias [10].  Nevertheless, few studies along those lines 
have been carried out.  One prospective cohort study (Adult Health Study) of atomic-bomb 
survivors―a longevity cohort with biennial health examinations―has been conducted at the 
Radiation Effects Research Foundation (RERF), and the study provides 
clinicoepidemiological data related to HCV infection and immunological status [11, 12].  
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Within the cohort study, we conducted a cross-sectional analysis for peripheral blood 
lymphocyte subsets among HCV persistently-infected, spontaneously-cleared, and uninfected 
groups, aiming to delineate immunological distinctions among these three groups.  We also 
aimed to identify the lymphocyte subsets that can predict hepatitis progression in 
HCV-persistent individuals, on the basis of a longitudinal analysis of time-course changes of 
platelet counts. 
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2. Materials and methods 
2.1. Study population 
The Atomic Bomb Casualty Commission, subsequently the RERF, established the Adult 
Health Study (AHS) cohort in 1958.  This cohort study enrolled a total of 23,000 
atomic-bomb survivors in Hiroshima and Nagasaki, who biennially received health 
examinations in outpatient clinics [11].  Hepatitis screening (HBsAg, anti-HBc Ab, anti-HBs 
Ab, and anti-HCV Ab tests, as well as HCV RNA test if anti-HCV Ab was positive) was 
conducted among 6,121 AHS participants in 1993 – 1995 [12].  Anti-HCV Ab negative 
subjects were categorized as the HCV-uninfected group in this study, whereas a “persistence” 
group was identified by anti-HCV Ab positive with detected HCV RNA, and a “spontaneous 
clearance” group was identified by anti-HCV Ab positive and undetectable HCV RNA.  
Subjects with hepatitis B virus surface antigen-positive were excluded from this study.  
From the 6,121 AHS subjects, lymphocyte subsets in the peripheral blood were then 
examined in 162 HCV persistence, 145 virus clearance, and 3511 uninfected subjects in 2000 
– 2002.  Most subjects (N = 120, 74%) in the persistence group (N = 162, including those 
with cancer history) were confirmed by a second RNA test at least two years after the first 
RNA test performed in 1993 – 1995.  Although the remaining 42 subjects in the group did 
not undergo the second RNA test, these subjects were confirmed to have developed type C 
chronic liver disease, based on medical chart review (e.g., treatment history, abdominal 
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sonographic observation, changes in platelet count, zinc sulfate turbidity, AST, and ALT, 
between 1993 – 1995 and 2000 – 2002) by a hepatologist (one of the authors, WO).  
Subsequent treatment data of hepatitis C from attending physicians were also taken into 
account.  No subjects in the persistence group underwent IFN therapy in 2000 – 2002. 
This study was approved by the RERF Human Investigation Committee, and all subjects 
gave written informed consent before each examination. 
 
2.2. Assays in hepatitis screening and clinical examinations 
In 1993 – 1995, anti-HCV Ab and hepatitis B virus surface antigen were examined using a 
second-generation passive hemagglutination kit and a reverse passive hemagglutination kit 
(Dynabott, Tokyo), as described previously [12].  Subjects were diagnosed as having Ab 
when agglutination was found in a serum diluted 25.  Qualitative and quantitative detection 
of HCV RNA was carried out using the Amplicor HCV ver. 2.0 and the Amplicor HCV 
monitor test ver. 1.0 and/or ver. 2.0 (Roche Diagnostics Systems, Tokyo, Japan). 
Platelet count decreases with progression of liver fibrosis, and this marker has widely been 
used as a reliable diagnostic tool for liver fibrosis/cirrhosis in patients with chronic HCV 
infection [13-16].  Postulated mechanisms for such platelet reduction include decreased 
secretion of the hematopoietic growth factor thrombopoietin from the liver and increased 
destruction of platelets by antiplatelet antibodies [17, 18].  Platelet count was routinely 
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measured in the AHS health examination, and an automatic blood cell counter (Coulter 
MAXM, Beckman Coulter, Inc. Tokyo, Japan) was used in 2000 – 2002.  Aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyltransferase (γ-GTP), and 
total cholesterol were also routinely measured, and an autoanalyzer (Hitachi 7180, Hitachi, 
Ltd., Tokyo, Japan) was used in 2000 – 2002. 
 
2.3. Information on lifestyle/environmental factors and clinical data 
  Information on alcohol drinking and smoking was obtained from questionnaires at the time 
of the AHS health examination in 1993 – 1995 and 2000 – 2002, respectively.  Body mass 
index (BMI) was measured at the AHS health examination in 2000 – 2002.  Radiation dose 
was estimated by the DS02 dosimetry system [19], based on the weighted skin dose computed 
as the gamma dose plus 10 times the neutron dose.  No subjects were diagnosed with HIV 
infection.  No subjects underwent organ transplantation or immunosuppressive therapy.  
Clinical information was obtained at the AHS examination in 2000 – 2002 as well as medical 
chart review, and classified according to the International Classification of Diseases (ICD) 
code. 
 
2.4. Lymphocyte subset analysis 
Circulating TH1 and TH2 cells can be straightforwardly enumerated by flow cytometry, 
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using cell surface markers for chemokine receptor, CXCR3, and prostaglandin D receptor, 
CRTH2, respectively [20, 21].  CD8 T cells expressing CXCR3, known as TC1, are also 
involved in the viral control during HCV infection [22].  We thus focused on TH1, TH2, TC1 
and TC2 cell subsets, as well as total CD4 T and CD8 T, NK, and B cell subsets in relation to 
HCV infection status. 
  Analytical flow cytometry was conducted in a FACScan machine (BD Biosciences, San 
Jose, CA), as described previously [23].  Monoclonal antibodies as specific cell surface 
markers were purchased from BD Pharmingen (San Diego, CA), unless otherwise noted.  
CD4 or CD8 T cells were enumerated as PerCP-labeled CD3 positive and PE-CD4 or 
FITC-CD8 positive cells; CD16 or CD20 cells were enumerated as PerCP-CD3 negative and 
FITC-CD16 (Beckman Coulter, Brea, CA) or PE-CD20 positive cells.  We used CXCR3 as 
a marker for TH1 and TC1 cells [20, 22] and CRTH2 for TH2 and TC2 cells [21].  Namely, 
TH1 and TH2 cells were identified with PerCP-CD4, FITC-CXCR3 (R&D Systems, 
Minneapolis, MN), and biotinylated CRTH2 (kindly provided by Dr. K. Nagata, BML, 
Kawagoe, Japan) plus PE-streptavidin; TC1 and TC2 cells were identified with PerCP-CD8, 
FITC-CXCR3, and biotinylated CRTH2 plus PE-streptavidin.  In every measurement, 
approximately 20,000 cells were analyzed. 
 
2.5. Statistical analysis 
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Two sample Wilcoxon or Pearson chi-square tests were performed to compare distributions 
of age, gender, city, radiation dose (Gy), smoking (packs/day), alcohol drinking (converted to 
grams of ethanol/day), BMI (kg/m2), AST (IU/L), ALT (IU/L), γ-GTP (U/L), total cholesterol 
(mg/dL), and platelet count (×104/μL) between all combinations of the three groups. 
Since aging and past radiation exposure likely influenced various immunological markers 
[23], these events were also evaluated in this study.  In each study group, the associations of 
lymphocyte subsets with age (at the time of examination), gender, radiation dose, and city 
were evaluated based on the multiple regression model [24]: 
log (subset percentages or ratios) = α + β1×age + β2×gender + β3×dose + β4×city + 
β5×alcohol + β6×smoking + β7×BMI + β8×autoimmune disease + β9×allergic disease + 
β10×cancer + β11×other non-cancer diseases 
where log is the logarithm at base 10, gender = 0 for male and 1 for female, city = 1 for 
Hiroshima and 2 for Nagasaki.  Smoking, alcohol drinking, BMI, autoimmune disease (1 if 
diagnosed, otherwise 0), allergic disease (1 or 0), cancer (1 or 0), and other non-cancer 
diseases (i.e., hypergammaglobulinemia and sarcoidosis, 1 or 0) were also used as additional 
explanatory variables. 
  We compared lymphocyte subset percentages or ratios between all combinations of the 
three groups in normal regression analysis with adjustment for age, gender, radiation dose, 
city, alcohol, smoking, BMI, autoimmune diseases, allergic diseases, and other non-cancer 
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diseases:  In the regression analysis, an explanatory variable regarding a group (one group =  
0, another group = 1) was used. 
  Regression analysis was also performed to investigate if there was any association between 
subset percentages or ratios and time-course changes in platelet counts through the period 
from 2000 through 2006.  Changes in platelet counts were calculated by: 
(platelet counts at the last examination – platelet counts at the first examination) / follow-up 
years. 
  In a regression analysis, a forward step-wise procedure was used for 8 immunological 
variables, %CD4, TH1, TH2, CD8, TC1, TC2, CD16, and CD20.  Four variables (%TH1, TC1, 
CD16, and CD20) were consequently selected (significance level to select, P < 0.2) to 
construct a statistical model.  All analyses were conducted using Stata software (Stata/SE 9.2 
for Windows, StataCorp LP, College Station, TX). 
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3. Results 
3.1. Basic characteristics of study subjects 
  Table 1 compares characteristics of study subjects in the HCV persistence, clearance, and 
uninfected groups.  The persistence group showed increased levels of blood γ-GTP, and 
decreased levels of total cholesterol and platelet counts, compared with the other two groups, 
indicating enhanced liver injury by persistent HCV infection.  The proportion of Hiroshima 
subjects in the persistence or clearance group was higher than that in the uninfected.  This is 
in accordance with the previous study that showed a higher anti-HCV Ab prevalence in 
Hiroshima atomic-bomb survivors than in Nagasaki survivors [12].  There were no 
significant differences in radiation dose by HCV infection status. 
This study primarily aimed to evaluate immunological alterations associated with HCV 
infection that might be modulated by age, gender, or past radiation exposure.  Therefore, the 
effects of those factors on lymphocyte subsets were first analyzed and are summarized in 
Supplemental Tables.  In the uninfected group, we found: i) age- and dose-dependent 
decreases in total CD4 T cell percentages, ii) higher total CD4 T cell percentages in females 
than in males, iii) no significant effects of age, gender, or radiation dose on total CD8 T cell 
percentages, iv) increased CD16 (NK) cell percentages with increasing age and higher 
percentages in males than in females, v) increased TH1 and TH2 cell percentages with 
increasing age and dose, and vi) both TH1/TH2 and TC1/TC2 cell ratios negatively or positively 
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associated with age and the female gender, respectively, but not with radiation dose 
(Supplemental Table 1).  The persistence and clearance groups also showed similar 
associations, although most associations were not statistically significant, probably due to 
smaller numbers of subjects in these groups (Supplemental Tables 2 and 3).  In addition to 
the three factors (age, gender, and radiation), other selected factors such as city, alcohol, 
smoking, and BMI also influenced various lymphocyte subsets (data not shown), and they 
were used as confounding variables in adjustments. 
 
3.2. Comparison of lymphocyte subsets among the HCV persistence, clearance, and 
uninfected groups 
  The study subjects having cancer history numbered 60, 32, and 698 in the persistence, 
clearance, and uninfected groups, respectively.  We then analyzed the lymphocyte subset 
alterations associated with HCV infection among subjects who have no history of cancer 
shown in Table 2, so as to eliminate potential effects of cancer development and/or cancer 
therapy (Table 3).  In addition, basic characteristics were not largely changed by excluding 
subjects with a history of cancer, but the radiation effects―specifically on TH1 and TH2 
cells―were no longer seen among subjects with no cancer history (data not shown). 
In the persistence group, TH1 and total CD8 T cell percentages and TH1/TH2 ratios were 
significantly higher than those in the HCV-uninfected group, while total CD4 T and CD16 
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cell percentages were lower.  Similar differences were also seen between the persistence and 
clearance groups.  However, except for total CD8 T cell percentages, no significant 
differences were observed between the clearance and uninfected groups. 
 
3.3. Relationship between lymphocyte subsets and progression of liver fibrosis in the 
HCV persistence group 
Next, we analyzed the relationship between lymphocyte subsets and platelet counts that had 
been longitudinally examined at the biennial AHS examination during 2000 - 2006 in the 
HCV persistence group, excluding subjects with cancer history (Table 4).  Average 
follow-up period was 4.7 years, and average decrement of platelet counts per year was -0.75 
(×104/μL).  We found that increased percentages of TH1 cells were associated with 
accelerated time-course reduction in platelet counts―accelerated progression of liver fibrosis 
(P = 0.027)―while TC1 and NK cell percentages were inversely associated with the 
progression (P = 0.027 and 0.058, respectively). 
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4. Discussion 
We investigated immunological alterations associated with HCV infection in a longevity 
study cohort of atomic-bomb survivors.  First, the effects of age, gender, and radiation on 
total CD4 T, CD8 T, and NK cells were studied in the uninfected group  (Supplemental 
Table 1) and found to be in close agreement with our previous studies [9, 23].  A new 
finding related to the uninfected group is that percentages of both TH1 and TH2 cells increased 
with increasing radiation dose and age.  That result is consistent with our previous findings 
in an expanded cohort of atomic-bomb survivors, which showed age- and radiation 
dose-dependent elevations of cytokine levels for both TH1-related cytokines (IFN-γ and 
TNF-α) and a TH2-related cytokine (IL-6) [25]. 
Second, we found that persistent HCV infection was associated with increases in TH1/TH2 
cell ratios and CD8 T cell percentages, and a decrease in NK cell percentages (Table 3).  
Regarding cytokine responses to persistent HCV infection, past reports in diversified patient 
groups were rather inconsistent: enhanced TH1 responses [26-29], TH2 responses [30-32], or 
both types [33, 34].  Although differing degrees of pathogenesis and/or inflammation among 
study patient groups may be in part responsible for this discrepancy [34, 35], some potential 
methodological drawbacks in studies demonstrating TH2 cytokine predominance were 
indicated [27].  The present study on lymphocyte subsets suggested enhanced TH1 immunity 
in persistent HCV infection, supporting a view that enhanced TH1 immunity alone is not 
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sufficient to regulate the virus in many cases of HCV infection. 
  As observed in this study, both decreased and increased percentages of peripheral NK 
cells and total CD8 T cells, respectively, have been reported in HCV persistence individuals 
[36-39].  A reduction in NK cells is assumed to be linked to ongoing viremia that may 
induce continuous proliferation of CD8 T cells.  A recent study on murine cytomegalovirus 
infection showed that NK cells negatively regulated the number and activity of virus-specific 
CD8 T cells as well as CD4 T cells that played a critical role in limiting viral persistence;  
lack of NK cell activation resulted in increased numbers of CD8 T and CD4 T cells along 
with enhanced effector functions through antigen-presentation by viral infected APCs [40].  
Such functional interplay among NK cells, APCs, and CD8 T cells may be common features 
in virally infected hosts.  It is also plausible that reduced NK cells of individuals may in part 
reflect their weakened natural immunity upon HCV infection, preferentially leading to failure 
of HCV-infected cell clearance [41]. 
Finally, our follow-up survey of the HCV persistence group showed that increased TH1 cell 
percentages were associated with accelerated progression of liver fibrosis, while TC1 and NK 
cell percentages were inversely associated with the progression (Table 4).  In accordance 
with preceding studies [26, 28, 42], this study demonstrates that TH1-immunity plays a vital 
role in HCV-related fibrosis progression.  In the liver as well as peripheral blood of 
individuals with chronic HCV infection, TH1 cells may enhance CTL response and 
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macrophage activation by producing cytokines such as IL-2, IFN-γ, and TNF-α, thereby 
facilitating the necroinflammatory process of hepatitis C [26, 42].  On the other hand, 
increased TC1 cell percentages in total CD8 T cells were associated with slower progression 
of fibrosis―new findings in this study.  TC1 cells express a chemokine receptor, CXCR3, 
which is required for migration to the HCV-infected liver [22], and we inferred that the 
increased TC1 fraction includes HCV-specific CD8 T cells.  Several studies have shown 
relationships between higher numbers of circulating as well as intrahepatic HCV-specific 
CD8 T cells and lesser degrees of liver fibrosis during chronic HCV infection [43-46]:  One 
plausible explanation is that HCV-specific CD8 T cells might control the virus without 
exerting cytotoxic effects on hepatocytes [46].  Alternatively, a population of CD8 T cells 
secreting an anti-fibrotic cytokine, IL-10, may be implicated in attenuation of hepatocyte 
killing and protection against liver injury [45, 47]. 
A limitation of this study is that we examined clinical and immunological data only from 
peripheral blood.  Intrahepatic lymphocytes are assumed to have features discrete from those 
in peripheral blood [48].  Also, our comparison of lymphocyte subsets among study groups 
was cross-sectional, making it difficult to identify immunological factors responsible for 
persistent HCV infection. 
In conclusion, this study identified immunological characteristics associated with HCV 
infection in a Japanese population and also indicated that peripheral TH1, TC1, and NK cell 
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subsets will be useful for predicting progression of hepatitis in persistently HCV-infected 
patients, and consequent development of hepatocellular carcinomas. 
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Characteristics of the study subjects
Persistence Clearance Uninfected
(anti-HCV + (anti-HCV + (anti-HCV -) Persistence vs. Clearance Persistence vs. Uninfected Clearance vs. Uninfected
/HCV RNA +) /HCV RNA -)
N =162 N = 145 N = 3511 P valuea P valuea P valuea
Ageb 71.7 (60.8-83.0) 72.3 (64.8-88.0) 72.2 (58.4-87.2) 0.041 0.79 0.029
Genderc
  Male  57 (35.2) 48 (33.1) 1078 (30.7) 0.70 0.23 0.54
  Female 105 (64.8) 97 (66.9) 2433 (69.3)
Cityc
  Hiroshima 112 (69.1) 96 (66.2) 2034 (57.9) 0.58 0.005 0.048
  Nagasaki  50 (30.9) 49 (33.8) 1477 (42.1)
Radiation dose (Gy)b 0.147 (0-2.658) 0.071 (0-1.890) 0.096 (0-2.032) 0.26 0.47 0.39
Smoking (pack/day)b 0 (0-1.0) 0 (0-1.0) 0 (0-1.0) 0.80 0.087 0.18
Alcohol drinking (gram/day)b 0 (0-85.0)d 0 (0-103.0)d 0 (0-69.8)d 0.35 0.57 0.062
BMI (kg/m2)b 22.4 (16.7-28.5) 22.6 (17.3-29.6) 22.7 (17.6-28.7) 0.46 0.084 0.58
AST (IU/L)b 21 (15-51) 21 (14-35) 22 (15-43) 0.15 0.85 0.081
ALT (IU/L)b 17 (9-46) 18 (9-42) 17 (9-44) 0.87 0.99 0.84
γ-GTP (U/L)b 28.5 (12.5-131.5) 25 (12-127) 24 (11-111) 0.10 < 0.001 0.29
Total cholesterol (mg/dL)b 168.5 (117-234) 206 (142-264) 208 (154-266) < 0.001 < 0.001 0.41
Platelet count (×104/μL)b 17.3 (7.2-28.2) 22.0 (14.3-30.8) 22.9 (14.5-33.7) < 0.001 < 0.001 0.031
aTwo-sample Wilcoxon rank-sum test, or Pearson chi-square test for gender and city.
bMedian (5-95% percentiles).
cNumber (%).
dThe percentages of never-drinkers were 59.3, 53.8, and 60.6 in the 3 groups, respectively.
Table 2
Characteristics of the study subjects with no cancer history
Persistence Clearance Uninfected
(anti-HCV + (anti-HCV + (anti-HCV -) Persistence vs. Clearance Persistence vs. Uninfected Clearance vs. Uninfected
/HCV RNA +) /HCV RNA -)
N =102 N = 113 N = 2813 P valuea P valuea P valuea
Ageb 71.5 (61.3-82.7) 72.3 (62.4-90.8) 72.0 (58.1-87.3) 0.026 0.64 0.021
Genderc
  Male 36 (35.3) 38 (33.6) 832 (29.6) 0.80 0.22 0.36
  Female 66 (64.7) 75 (66.4) 1981 (70.4)
Cityc
  Hiroshima 70 (68.6) 77 (68.1) 1613 (57.3) 0.94 0.023 0.023
  Nagasaki 32 (31.4) 36 (31.9) 1200 (42.7)
Radiation dose (Gy)b 0.031 (0-1.862) 0.056 (0-1.890) 0.072 (0-1.878) 0.84 0.68 0.49
Smoking (pack/day)b 0 (0-1.0) 0 (0-1.0) 0 (0-1.0) 0.67 0.070 0.18
Alcohol drinking (gram/day)b 0 (0-90)d 0 (0-105.8)d 0 (0-69.8)d 0.067 0.76 0.014
BMI (kg/m2)b 22.6 (16.7-28.5) 22.6 (17.3-29.6) 22.9 (17.7-28.8) 0.49 0.097 0.55
AST (IU/L)b 22 (15-50) 21 (13-37) 22 (15-42) 0.12 0.34 0.26
ALT (IU/L)b 18 (9-39) 17 (9-48) 17 (9-44) 0.57 0.69 0.69
γ-GTP (U/L)b 26 (12-100) 27 (12-127) 23 (11-106) 0.99 0.19 0.18
Total cholesterol (mg/dL)b 175 (124-243) 211 (136-272) 209 (157-266) < 0.001 < 0.001 0.46
Platelet count (×104/μL)b 19.3 (10.3-32.0) 21.7 (14.2-30.8) 23.0 (14.8-33.7) < 0.001 < 0.001 0.006
aTwo-sample Wilcoxon rank-sum test, or Pearson chi-square test for gender and city.
bMedian (5-95% percentiles).
cNumber (%).
dThe percentages of never-drinkers were 64.7, 50.4, and 61.1 in the 3 groups, respectively.
Table 3
Comparisons of peripheral lymphocyte subsets among subjects with no cancer history
Persistence Clearance Uninfected Persistence vs. Clearance Persistence vs. Uninfected Clearance vs. Uninfected
N = 102 N = 113 N = 2813  P valuea  P valuea  P valuea
CD4 (%)b 40.8 (8.9) 42.2 (9.0) 43.0 (8.9) 0.32 0.007 0.46
TH1 (%)
b 35.2 (9.6) 27.1 (8.7) 26.0 (8.9) < 0.001 < 0.001 0.23
TH2 (%)
b 1.55 (0.88) 1.74 (1.03) 1.79 (1.10) 0.54 0.11 0.65
TH1/TH2
b 30.7 (20.6) 20.8 (12.8) 20.8 (23.0) < 0.001 < 0.001 0.27
CD8 (%)b 23.4 (9.6) 20.9 (7.9) 19.0 (7.8) 0.20 < 0.001 0.040
TC1 (%)
b 42.3 (14.7) 38.8 (15.2) 39.5 (14.6) 0.25 0.17 0.68
TC2 (%)
b 2.78 (3.72) 2.87 (4.03) 3.35 (5.09) 0.34 0.68 0.40
TC1/TC2
b 42.8 (45.8) 50.9 (78.2) 51.1 (91.4) 0.66 0.38 0.51
CD4/CD8b 2.08 (1.02) 2.42 (1.35) 2.75 (1.57) 0.15 < 0.001 0.054
CD16 (%)b 14.0 (9.4) 17.0 (8.8) 17.1 (9.4) 0.035 < 0.001 0.82
CD20 (%)b 14.5 (7.6) 13.5 (5.3) 13.9 (6.1) 0.95 0.44 0.60
aTest of difference of logarithmic values between two groups using normal regression analysis with adjustment for age, gender, city, radiation dose, alcohol, smoking, BMI,





                        Unadjusted                            Adjusteda                            Adjustedb
Explanatory variables coefficient P value coefficient P value coefficient P value
Age (+10 yrs) -0.26 0.33 － － － －
Gender (female vs. male) 0.43 0.21 － － － －
Radiation dose (Gy) 0.28 0.26 － － － －
City (Nagasaki vs. Hiroshima) 0.00 0.99 － － － －
Log CD4 -0.25 0.86 1.11 0.50 － －
Log TH1 -1.90 0.13 -2.38 0.086 -3.19 0.027
Log TH2 -0.53 0.41 -0.34 0.65 － －
Log TH1/TH2 0.03 0.97 -0.31 0.67 － －
Log CD8 -1.72 0.060 -2.63 0.011 － －
Log TC1 1.66 0.068 2.05 0.041 2.36 0.027
Log TC2 -0.30 0.37 0.23 0.57 － －
Log TC1/TC2 0.51 0.12 0.10 0.81 － －
Log CD4/CD8 1.04 0.16 2.03 0.015 － －
Log CD16 0.73 0.21 1.13 0.062 1.18 0.058
Log CD20 1.10 0.11 1.04 0.15 1.03 0.17
 
aRegression model:  decrements in platelet counts =  α + β 1  × log (lymphocyte subset) + β 2  × age + β 3  × gender + β 4  × dose + β 5  × city
   + β 6  × alcohol + β 7  × smoking  + β 8  × BMI + β 9  × autoimmune disease + β 10  × allergic disease + β 11  × other non-cancer diseases.
bForward step-wise procedure (P < 0.2) was used for 8 lymphocyte variables (CD4, TH1, TH2, CD8, TC1, TC2, CD16, and CD20).
Selected 4 variables (TH1, TC1, CD16, and CD20) were used in the regression analysis with 10 explanatory variables in footnote a.
Regresson analysis of decrements (per year) in platelet counts among HCV persistence subjects with no cancer history (N = 96)
